437 related articles for article (PubMed ID: 2497946)
1. Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.
Naylor CD; Armstrong PW
CMAJ; 1989 Jun; 140(11):1289-99. PubMed ID: 2497946
[TBL] [Abstract][Full Text] [Related]
2. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
GUSTO investigators
N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
[TBL] [Abstract][Full Text] [Related]
4. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
5. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
Goel V; Naylor CD
Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
[TBL] [Abstract][Full Text] [Related]
6. Thrombolytic treatment in acute myocardial infarction.
Verstraete M
Circulation; 1990 Sep; 82(3 Suppl):II96-109. PubMed ID: 2118432
[TBL] [Abstract][Full Text] [Related]
7. Intravenous thrombolytic therapy in myocardial infarction: an analytical review.
Shammas NW; Zeitler R; Fitzpatrick P
Clin Cardiol; 1993 Apr; 16(4):283-92. PubMed ID: 8458108
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.
Magnani B
J Am Coll Cardiol; 1989 Jan; 13(1):19-26. PubMed ID: 2491867
[TBL] [Abstract][Full Text] [Related]
9. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Lancet; 1990 Jul; 336(8707):65-71. PubMed ID: 1975321
[TBL] [Abstract][Full Text] [Related]
10. Accelerated infusion of streptokinase in acute myocardial infarction results in better TIMI flow grade in infarct-related artery.
Dwivedi SK; Saran RK; Narain VS; Bansal S; Gupta R; Puri VK
Indian Heart J; 2000; 52(1):40-4. PubMed ID: 10820932
[TBL] [Abstract][Full Text] [Related]
11. Safety of helicopter transport and out-of-hospital intravenous fibrinolytic therapy in patients with evolving myocardial infarction.
Topol EJ; Fung AY; Kline E; Kaplan L; Landis D; Strozeski M; Burney RE; Pitt B; O'Neill WW
Cathet Cardiovasc Diagn; 1986; 12(3):151-5. PubMed ID: 3089627
[TBL] [Abstract][Full Text] [Related]
12. [Thrombolytic treatment in acute myocardial infarction. Choice of preparations in Norwegian hospitals].
Andreassen AK; Gullestad L; Endresen K
Tidsskr Nor Laegeforen; 1998 Jun; 118(17):2630-1. PubMed ID: 9673511
[TBL] [Abstract][Full Text] [Related]
13. A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study).
Taylor GJ; Moses HW; Koester D; Colliver JA; Katholi RE; Dove JT; Woodruff RC; Mikell FL; Becker LC; Sheehan FH
Am J Cardiol; 1993 Nov; 72(14):1010-4. PubMed ID: 8213579
[TBL] [Abstract][Full Text] [Related]
14. Thrombolytic therapy in acute coronary thrombosis.
Ramalanjaona GR; Mathew JC
Indiana Med; 1990 Jun; 83(6):410-2. PubMed ID: 2112180
[TBL] [Abstract][Full Text] [Related]
15. [Thrombolysis in acute myocardial infarction. Streptokinase or r-TPA?].
Silva LA; Ribeiro E; Carneiro RC; Kaissar S; Reis Filho A; Torossian SP; Tavares JR; Buffolo E; Amino JG; Duprat Filho R
Arq Bras Cardiol; 1990 Jul; 55(1):13-7. PubMed ID: 2127353
[TBL] [Abstract][Full Text] [Related]
16. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator.
Peuhkurinen K; Risteli L; Jounela A; Risteli J
Am Heart J; 1996 Jan; 131(1):7-13. PubMed ID: 8554022
[TBL] [Abstract][Full Text] [Related]
17. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
Rao AK; Pratt C; Berke A; Jaffe A; Ockene I; Schreiber TL; Bell WR; Knatterud G; Robertson TL; Terrin ML
J Am Coll Cardiol; 1988 Jan; 11(1):1-11. PubMed ID: 3121710
[TBL] [Abstract][Full Text] [Related]
18. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
Lessler DS; Avins AL
Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400
[TBL] [Abstract][Full Text] [Related]
19. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
[TBL] [Abstract][Full Text] [Related]
20. [Endovenous thrombolysis in acute myocardial infarct. The experience in a community hospital. An analysis of 120 patients].
Jorge Sdo C
Arq Bras Cardiol; 1992 Jul; 59(1):23-30. PubMed ID: 1341143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
